Immunocore Holdings plc(NASDAQ:IMCR) 
Immunocore Holdings plc, a late-stage biotechnology company, develops immunotherapies for the treatment of oncology, infectious, and autoimmune diseases. The company's lead oncology therapeutic candidate is tebentafusp, which is in a randomized Phase 3 clinical trial in patients with previously untr...
Share this website to your friends
The information provided in this report is taken from www.sec.gov. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Day
Week
Month
Date 2025-04-04
P
O 28.32
H 28.55
L 27.19
C 27.26
V 291,778
10EMA 27.26
20EMA 27.26
60EMA 27.26
120EMA 27.26
250EMA 27.26